Stockreport

Exelixis Files Zanzalintinib With FDA As Valuation Signals Upside Potential [Yahoo! Finance]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF Exelixis (NasdaqGS:EXEL) has submitted an FDA application for zanzalintinib, its next generation cancer therapy, in metastatic colorectal cancer. The filing covers us [Read more]